Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Epiretinal Membrane
Interventions: 27-gauge vitrectomy wound construction; Device
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystoid Macular Edema
Interventions: Pegaptanib Sodium, Control; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration
Interventions: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sargramostim, Ganciclovir; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Sherman Oaks, California + 7 more

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad pegol (ACP); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Not listed
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Brolucizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 9,457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Age-Related Macular Degeneration
Interventions: 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more

Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Interventions: Sirolimus; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 56 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Detachment, Full Thickness Macular Hole, Epiretinal Membrane
Interventions: Pars plana vitrectomy, External drainage; Procedure
Lead sponsor: Allen C. Ho, MD; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions: Remigromig, Aflibercept 2.0 mg; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more

Conditions: Diabetic Macular Edema
Interventions: 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more

Conditions: Glaucoma, Retinal Disease, Corneal Disease
Interventions: Nidek Mirante, Optovue RTVue XR Avanti, Optos P200DTx; Device
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 22 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Age-Related Macular Degeneration
Interventions: occupational therapy interventions for low vision care; Combination Product
Lead sponsor: MCPHS University; Other
Eligibility: 50 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Retinopathy of Prematurity (ROP)
Interventions: 1% phenylephrine and 0.2% cyclopentolate; Drug
Lead sponsor: Georgetown University; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Interventions: Not listed
Lead sponsor: Optina Diagnostics Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Miami, Florida • Las Vegas, Nevada • Norfolk, Virginia + 1 more

Conditions: Retinoschisis, X-Linked
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: PF-04523655; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Beverly Hills, California • Pasadena, California • Walnut Creek, California + 5 more

Conditions: Retinoblastoma
Interventions: Proton Beam Radiation Therapy, Ophthalmic EUA; Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Choroideremia
Interventions: BIIB111; Genetic
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more

Conditions: Age Related Macular Degeneration (ARMD)
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Sun City, Arizona • Huntington Beach, California + 28 more

Conditions: Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions: Photobiomodulation, Ketogenic diet; Behavioral
Lead sponsor: Bristlecone Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: In-Person Eye Examination; Other
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 3
States / cities: Los Angeles, California

Conditions: Retinitis Pigmentosa
Interventions: NAC effervescent tablets; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Sirolimus for Advanced Age-Related Macular Degeneration

Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

Inflammasomes in Cell Death in FTMH, ERM, and RRD

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Agreement and Precision Study of the Nidek Mirante

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

Study on Effective Mydriasis in Premature Infants

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images

FIGHT-RP 1 Extension Study